COMPARATIVE STUDY
JOURNAL ARTICLE

3'-deoxy-3'-[¹⁸F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer: comparison with [¹⁸F]-FDG PET/CT

Haojun Chen, Yimin Li, Hua Wu, Long Sun, Qin Lin, Long Zhao, Hanxiang An
Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al] 2015, 191 (2): 141-52
25163419

PURPOSE: The purpose of this work was to investigate the prognostic value of response analysis using early 3'-deoxy-3'-[(18)F]-fluorothymidine ((18)F-FLT) PET/CT in esophageal squamous cancer patients and make a comparison with [(18)F]-fluorodeoxyglucose ((18)F-FDG) PET/CT.

PATIENTS AND MATERIALS: For 34 patients with esophageal squamous cell cancer, both (18)F-FLT PET/CT and (18)F-FDG PET/CT scans were performed at baseline (pre), 4 weeks after the start of radiotherapy or chemoradiotherapy (interim), and 2 weeks after therapy completion (final). SUVmax1, SUVmax2, and SUVmax3 represent SUVmax (SUV: standard uptake values) measured on the pre, interim, and final scans, respectively. GTVFLT-PET and GTVFDG-PET (GTV: gross tumor volume) were measured on the pre and interim scans. ΔSUV/ΔGTV represents the fractional changes of SUVmax/GTV between two different time points. PET parameters were evaluated for correlations with outcome.

RESULTS: Regarding (18)F-FLT PET/CT, according to receiver operating characteristic (ROC) curve analysis, parameters for predicting 2-year progression-free survival (PFS) and locoregional control (LRC) showed the highest area under curve (AUC) on interim (18)F-FLT PET/CT scans (ΔSUV12, AUC of 0.812 for PFS, 0.775 for LRC, with a cutoff of 60 %; P = 0.008), compared with the parameters on pre and final scans. Patients with a ΔSUV12 greater than 60 %, who were defined as interim PET-negative group, were associated with better 2-year PFS and LRC than the interim PET-positive group (PFS: 70.6 % vs. 35.2 %, P = 0.025; LRC: 84.2 % vs 52.9, P = 0.046). In terms of (18)F-FDG PET/CT, ΔSUV13 on the final 18F-FDG PET/CT scan demonstrated better prediction (AUC of 0.812 for PFS, 0.807 for LRC, with a cutoff of 75 %; P = 0.016) than the parameters on pre and interim scans. An SUVmax decrease ≥ 75 % on the final (18)F-FDG PET/CT scan was associated with better clinical outcome (PFS: 73.3 % vs. 36.8 %, P = 0.022; LRC: 86.7 % vs 52.6, P = 0.029). These correlations were most prominent in the subgroup of patients treated with chemoradiotherapy.

CONCLUSION: Early interim (18)F-FLT PET/CT is a significant predictor of 2-year PFS and LRC, which is correlated better with early responses and late outcomes than interim (18)F-FDG PET/CT in esophageal squamous cancer patients.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read
25163419
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"